Suppliers / Wuhan Calmland Pharmaceuticals

Wuhan Calmland Pharmaceuticals

China Updated 9 July 2026

Wuhan Calmland Pharmaceuticals is an API manufacturer based in China. It holds 7 active US drug master files and 5 valid CEPs across a filed portfolio of 8 molecules. Its most recent recorded inspection, by US FDA, closed on 12 July 2019 as VAI.

7
active US DMFs
5
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 12 July 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Wuhan, China Not on file
China, China 3012447405

What they file, and where

Molecule Regulators Docs
Docetaxel EDQM, US FDA 2
Epinastine EDQM, US FDA 2
Paclitaxel EDQM, US FDA 2
Pemetrexed US FDA 2
Pemetrexed Disodium EDQM, SFDA (Saudi Arabia) 2
Decitabine US FDA 1
Mitoxantrone EDQM 1
Tenofovir Disoproxil US FDA 1

Also appears on these molecule pages

Paclitaxel API Tenofovir Disoproxil API

Comparing suppliers?

Choose your molecules and target markets. Wuhan Calmland Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 12 July 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability